Accuray Incorporated (NASDAQ:ARAY) Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP lowered its holdings in Accuray Incorporated (NASDAQ:ARAY) by 18.3% during the third quarter, Holdings Channel reports. The fund owned 366,794 shares of the medical equipment provider’s stock after selling 82,367 shares during the quarter. GSA Capital Partners LLP’s holdings in Accuray were worth $660,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. The Manufacturers Life Insurance Company increased its stake in shares of Accuray by 13.3% in the second quarter. The Manufacturers Life Insurance Company now owns 44,936 shares of the medical equipment provider’s stock worth $82,000 after acquiring an additional 5,273 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Accuray by 9.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 73,146 shares of the medical equipment provider’s stock worth $181,000 after acquiring an additional 6,583 shares during the period. Renaissance Technologies LLC increased its stake in shares of Accuray by 0.3% in the second quarter. Renaissance Technologies LLC now owns 2,812,184 shares of the medical equipment provider’s stock worth $5,118,000 after acquiring an additional 7,500 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Accuray by 3.3% in the second quarter. Bank of New York Mellon Corp now owns 279,426 shares of the medical equipment provider’s stock worth $509,000 after acquiring an additional 8,864 shares during the period. Finally, Nisa Investment Advisors LLC increased its stake in shares of Accuray by 253,483.3% in the second quarter. Nisa Investment Advisors LLC now owns 15,215 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 15,209 shares during the period. Institutional investors and hedge funds own 64.08% of the company’s stock.

Accuray Stock Performance

Shares of NASDAQ ARAY opened at $1.70 on Tuesday. The company’s fifty day moving average price is $1.86 and its 200 day moving average price is $1.83. Accuray Incorporated has a 1 year low of $1.40 and a 1 year high of $3.05. The company has a market capitalization of $170.97 million, a PE ratio of -10.00 and a beta of 1.40. The company has a debt-to-equity ratio of 3.59, a quick ratio of 0.87 and a current ratio of 1.63.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. The firm had revenue of $101.55 million for the quarter, compared to the consensus estimate of $98.10 million. During the same period in the prior year, the firm posted ($0.03) earnings per share. On average, research analysts predict that Accuray Incorporated will post 0.01 earnings per share for the current year.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of Accuray from a “buy” rating to a “hold” rating in a research note on Friday.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.